Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
This article was originally published in PharmAsia News
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.
You may also be interested in...
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.
Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.